Series A1 July 2020

MIP Diagnostics secures £5.1m Series A funding to expand commercial operations and production.

Downing Ventures, BGF, Mercia, and Calculus Capital backed the Bedfordshire nanotechnology business in its latest round.

£5.1MSeries A

MIP Diagnostics is a nanotechnology business based in Bedfordshire that develops and manufactures synthetic antibodies known as nanoMIPs. These nanoscale polymers serve as robust alternatives to traditional antibodies for use in diagnostic devices and biosensors.

MIP Diagnostics has secured a £5.1m Series A funding round to accelerate its international expansion and scale up production capabilities. Downing Ventures, BGF, Mercia Asset Management, and Calculus Capital participated in the latest syndicate, with Downing Ventures, BGF, and Calculus Capital leading the investment. The Bedfordshire company intends to deploy the capital to build out its research and development team, increase commercial resources, and expand manufacturing operations amid growing global demand for synthetic antibody alternatives.

From the founder

"We are delighted to be bringing such high-profile investors on board, who share our ambitious growth plans for the business. This significant investment is a strong endorsement of the MIPs technology, it will enable us to scale our operations and take the business to the next level. MIPs offer many advantages and provide solutions to enable new applications that push the limit of what was previously possible. This investment will enable us to rapidly expand our operations to service these opportunities and bring exciting new products to the market."

Stephane Argivier

CEO at MIP Diagnostics

Investor perspective

"We quickly identified the value and advantages that MIP’s could bring to expand diagnostics and measuring both in the healthcare and other industries. Along with the rest of the syndicate we believe that this technology and the strong and experienced management team can lead MIP Diagnostics to become a leading UK technology company."

Will Brooks

Investment Director, Downing Ventures